Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Documenti analoghi

• Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations
  di: Cassidy A. Gutner, et al.
  Pubblicazione: (2024)
• Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study
  di: Ricky K. Hsu, et al.
  Pubblicazione: (2024)
• Mother‐child dyads living with HIV in the Western Cape, South Africa: Undetectable = Undetectable?
  di: Kim Anderson, et al.
  Pubblicazione: (2025)
• Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities
  di: Jesse A. Heitner, et al.
  Pubblicazione: (2026)
• Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study
  di: Katherine L. Nelson, et al.
  Pubblicazione: (2025)